Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003088-200241040-00003PMID 11978145
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Experience with Cabergoline in Patients with Advanced Parkinson’s Disease Treated with Levodopa

  2012cited by this paper
• Epidemiology and Genetics of Essential Tremor

  2008cited by this paper
• Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies

  2005cited by this paper
• Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa

  2004cited by this paper
• Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease

  2004cited by this paper
• Systemic availability of orally administered L-dopa in the elderly Parkinsonian patient

  2004cited by this paper
• Biperiden effects and plasma levels in volunteers

  2004cited by this paper
• Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

  2004cited by this paper
• Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level

  2004cited by this paper
• Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

  2004cited by this paper
• Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of procyclidine in man

  2004cited by this paper
• Amantadine in Parkinson's disease.

  2003cited by this paper
• The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers.

  2003cited by this paper
• Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.

  2003cited by this paper
• A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy

  2001cited by this paper
• Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease

  2001cited by this paper
• Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons.

  2000cited by this paper
• Clinical Pharmacokinetics of Ropinirole

  2000cited by this paper
• COMT inhibition in Parkinson's disease: rationale and clinical relevance.

  2000cited by this paper
• Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease

  2000cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers.

  2000cited by this paper
• Tolcapone and Hepatotoxic Effects

  2000cited by this paper
• Multiple-Dose Pharmacokinetics of Selegiline and Desmethylselegiline Suggest Saturable Tissue Binding

  2000cited by this paper
• Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.

  2000cited by this paper
• Ropinirole: a review of its use in the management of Parkinson's disease.

  2000cited by this paper
• Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.

  2000cited by this paper
• Sleep attacks and Parkinson's disease treatment.

  2000cited by this paper
• Structure and function of dopamine receptors.

  2000cited by this paper
• Selegiline and mortality in subjects with Parkinson’s disease

  2000cited by this paper
• Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

  2000cited by this paper
• The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa

  2000cited by this paper
• Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.

  1999cited by this paper
• Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity.

  1999cited by this paper
• Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges

  1999cited by this paper
• The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease.

  1999cited by this paper
• Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine.

  1999cited by this paper
• Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.

  1999cited by this paper
• The effect of tolcapone on the pharmacokinetics of benserazide

  1999cited by this paper
• Pergolide monotherapy in the treatment of early PD

  1999cited by this paper
• Immediate-release and controlled-release carbidopa/levodopa in PD

  1999cited by this paper
• Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

  1999cited by this paper
• Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa‐treated parkinsonian patients

  1999cited by this paper
• Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects

  1999cited by this paper
• Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.

  1999cited by this paper
• Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study

  1999cited by this paper
• Muscarinic receptor occupancy by biperiden in living human brain.

  1999cited by this paper
• COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).

  1999cited by this paper
• [Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy].

  1999cited by this paper
• Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  1999cited by this paper
• Amantadine-induced peripheral neuropathy

  1999cited by this paper
• Pathophysiology of L-dopa-induced dyskinesias.

  1999cited by this paper
• Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.

  1999cited by this paper
• Stereoselective determination of trihexyphenidyl in human serum by LC-ESI-MS.

  1999cited by this paper
• Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole

  1999cited by this paper
• A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease

  1999cited by this paper
• Apomorphine protects against MPTP‐induced neurotoxicity in mice

  1999cited by this paper
• In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity.

  1999cited by this paper
• Pharmacodynamics of the long-duration response to levodopa in PD

  1999cited by this paper
• [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].

  1998cited by this paper
• Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon

  1998cited by this paper
• Current status of selegiline as a neuroprotective agent in Parkinson's disease.

  1998cited by this paper
• Selegiline delays the onset of disability in de novo parkinsonian patients

  1998cited by this paper
• Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone

  1998cited by this paper
• Early Treatment of Parkinson’s Disease with Cabergoline Delays the Onset of Motor Complications

  1998cited by this paper
• Tolcapone and fulminant hepatitis.

  1998cited by this paper
• A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease

  1998cited by this paper
• Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations

  1998cited by this paper
• Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

  1998cited by this paper
• A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease

  1998cited by this paper
• An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology.

  1998cited by this paper
• An algorithm (decision tree) for the management of Parkinson's disease

  1998cited by this paper
• Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.

  1998cited by this paper
• The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

  1998cited by this paper
• Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.

  1998cited by this paper
• Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

  1998cited by this paper
• Levodopa Toxicity and Apoptosis

  1998cited by this paper
• Endogenous dopamine-derived neurotoxins and Parkinson's disease.

  1998cited by this paper
• Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa

  1998cited by this paper
• Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease

  1998cited by this paper
• Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

  1998cited by this paper
• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• Pharmacology of Pramipexole, a Dopamine D3-Preferring Agonist Useful in Treating Parkinson's Disease

  1998cited by this paper
• Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites *

  1998cited by this paper
• A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

  1998cited by this paper
• A Six‐month Study of Pergolide and Levodopa in De Novo Parkinson's Disease Patients

  1998cited by this paper
• Effect of selegiline on mortality in patients with Parkinson's disease

  1998cited by this paper
• An algorithm (decision tree) for the management of Parkinson’s disease (2001):

  1998cited by this paper
• Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone

  1998cited by this paper
• Clinical Pharmacology of Dopamine Agonists in Parkinson’s Disease

  1998cited by this paper
• Levodopa: Is toxicity a myth?

  1998cited by this paper
• Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations

  1997cited by this paper
• Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

  1997cited by this paper
• The long-duration action of levodopa may be due to a postsynaptic effect.

  1997cited by this paper
• Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.

  1997cited by this paper
• Tolcapone in stable Parkinson's disease

  1997cited by this paper
• Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.

  1997cited by this paper
• Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study.

  1997cited by this paper

• Altered pharmacokinetics of selected neurological drugs in patients with chronic kidney disease

  2025cites this paper
• Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction

  2025cites this paper
• Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson's Disease: Discovery and Characterization of New Inhibitors.

  2025cites this paper
• Objective real-world mobility patterns in Parkinson's disease: Driving and walking after levodopa dosing.

  2025cites this paper
• Hydrophilic and Amphiphilic Macromolecules as Modulators of the Physical Stability and Bioavailability of Piribedil: A Study on Binary Mixtures and Micellar Systems

  2025cites this paper
• Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease

  2025cites this paper
• Efficacy and safety of levodopa in secondary dystonia due to neurological Wilson disease (LIDWID)

  2025cites this paper
• MQPD: An Antioxidant Quinone–Dopamine Hybrid Which Induces Sustained Brain Dopamine Elevation

  2025cites this paper
• Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders

  2025cites this paper
• The on-going quest for a long-acting oral form of levodopa

  2025cites this paper
• Clinical and electrophysiological characteristics of large and small fiber neuropathy in Parkinson's disease.

  2025cites this paper
• Pallidal activity in Parkinson's disease patients with intraoperative dyskinesias.

  2025cites this paper
• Disorders of Consciousness and pharmacotherapy: a systematic update on drugs inducing consciousness improvement.

  2025cites this paper
• Does drug repurposing bridge the gaps in management of Parkinson's disease? Unravelling the facts and fallacies.

  2025cites this paper
• Neuroprotective potential of epigallocatechin gallate in Neurodegenerative Diseases: Insights into molecular mechanisms and clinical Relevance.

  2025cites this paper
• New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?

  2025cites this paper
• Parkinsonism-Hyperpyrexia Syndrome in a patient undergoing upper gastrointestinal surgery: A case report

  2024cites this paper
• Advancements in ultrasound-mediated drug delivery for central nervous system disorders

  2024cites this paper
• Levodopa: From Biological Significance to Continuous Monitoring

  2024cites this paper
• Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms

  2024cites this paper
• Optimization of oral entacapone administration in patients undergoing levodopa-carbidopa intestinal gel treatment.

  2024cites this paper
• Herb‐drug interactions: A short review on central and peripheral nervous system drugs

  2024cites this paper
• Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease.

  2024cites this paper
• Dopamine receptor agonist pramipexole exerts neuroprotection on global cerebral ischemia/reperfusion injury by inhibiting ferroptosis.

  2024cites this paper
• Therapeutic drug monitoring in Parkinson’s disease

  2024cites this paper
• Informing future randomized controlled trials of amantadine hydrochloride in neurocritical care and post-neurocritical care stroke patients through a retrospective study

  2024cites this paper
• Probing solution conformations of l-DOPA: Integration of experiment and simulation via vibrational optical activity.

  2024cites this paper
• Molecular Communication-Based Intelligent Dopamine Rate Modulator for Parkinson’s Disease Treatment

  2024cites this paper
• Mucuna pruriens, a Possible Treatment for Depressive Disorders

  2024cites this paper
• Pharmacology in Treatment of Patients with Disorders of Consciousness.

  2023cites this paper
• Importance of glucose and its metabolism in neurodegenerative disorder, as well as the combination of multiple therapeutic strategies targeting α-synuclein and neuroprotection in the treatment of Parkinson's disease.

  2023cites this paper
• Piperine improves levodopa availability in the 6‐OHDA‐lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase

  2023cites this paper
• Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?

  2023influential citation
• Five most important drug interactions in the critically ill

  2023cites this paper
• Neurodegenerative Etiology of Aromatic L-Amino Acid Decarboxylase Deficiency: a Novel Concept for Expanding Treatment Strategies

  2023cites this paper
• Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration.

  2023cites this paper
• In Vitro and In Vivo Evaluation of Carbopol 71G NF-Based Mucoadhesive Minitablets as a Gastroretentive Dosage Form.

  2023cites this paper
• Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.

  2023cites this paper
• Treatment of Parkinson's disease in Iranian ancient medicine

  2023cites this paper
• Effects of different doses of dopamine receptor agonist pramipexole on neurobehaviors and changes of mitochondrial membrane potentials in rats with global cerebral ischemia-reperfusion injury.

  2023cites this paper
• G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

  2023cites this paper
• Unveiling the antioxidant potential of newly designed Phenylethylamine derivatives through computational chemistry: Significance of acid dissociation constants

  2023cites this paper
• Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

  2023cites this paper
• Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease

  2022cites this paper
• Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

  2022cites this paper
• ROPINIROLE VERSUS LEVODOPA: BETTER CLINICAL BENEFITS IN PARKINSON’S DISEASE

  2022influential citation
• Gut bacterial aromatic amine production: aromatic amino acid decarboxylase and its effects on peripheral serotonin production

  2022cites this paper
• Association Between Microbial Tyrosine Decarboxylase Gene and Levodopa Responsiveness in Patients With Parkinson Disease

  2022influential citation
• Drug reprofiling history and potential therapies against Parkinson’s disease

  2022influential citation
• The Anti-Parkinson Potential of Gingko biloba-Supplement Mitigates Cortico-Cerebellar Degeneration and Neuropathobiological Alterations via Inflammatory and Apoptotic Mediators in Mice

  2022cites this paper
• Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase.

  2022cites this paper
• Recent Trend of Ultrasound-Mediated Nanoparticle Delivery for Brain Imaging and Treatment.

  2022cites this paper
• Development and Validation of New RP-HPLC Method for Estimation of Pramipexole Dihydrochloride in Bulk and Pharmaceutical Formulation

  2022cites this paper
• Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease

  2022cites this paper
• Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability.

  2021cites this paper
• Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone

  2021cites this paper
• DFT, NBO, HOMO-LUMO, NCI, stability, Fukui function and hole – Electron analyses of tolcapone

  2021cites this paper
• Design, Optimization and Pharmacokinetic Evaluation of Piribedil Loaded Solid Lipid Nanoparticles Dispersed in Nasal In Situ Gelling System for Effective Management of Parkinson's Disease.

  2021cites this paper
• ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

  2021cites this paper
• Regenerative nanomedicine applications for neurodegenerative diseases of central nervous system

  2021cites this paper
• Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation

  2021cites this paper
• Practical aspects of prescribing antiparkinsonian drugs. The place of amantadines in the management of Parkinson’s disease

  2021cites this paper
• Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease.

  2021cites this paper
• Gut microbiota in Parkinson’s disease patients: hospital-based study

  2021cites this paper
• Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease

  2021cites this paper
• Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder

  2021cites this paper
• Interaction and esterase activity of albumin serums with orphenadrine: A spectroscopic and computational approach

  2021cites this paper
• Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?

  2021cites this paper
• Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial

  2021cites this paper
• Levodopa Inhalation Powder: A Review in Parkinson’s Disease

  2020cites this paper
• Piribedil loaded thermo-responsive nasal in situ gelling system for enhanced delivery to the brain: formulation optimization, physical characterization, and in vitro and in vivo evaluation

  2020cites this paper
• Bromocriptine as a Novel Pharmacological Chaperone for Mucopolysaccharidosis IV A.

  2020cites this paper
• A dose-dependent pharmacokinetic study of levodopa by intramuscular administration in rabbits

  2020cites this paper
• The potential role of metformin in the treatment of Parkinson's disease

  2020cites this paper
• Positron Emission Tomography of the

  2020cites this paper
• Recent Advancement in Clinical Application of Nanotechnological Approached Targeted Delivery of Herbal Drugs

  2020cites this paper
• Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.

  2020cites this paper
• Nonlinear pharmacodynamics of levodopa through Parkinson's disease progression.

  2020cites this paper
• Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment

  2020cites this paper
• Meta-analysis of the gut microbiome of Parkinson's disease patients suggests alterations linked to intestinal inflammation

  2020cites this paper
• Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update

  2020cites this paper
• LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product.

  2020cites this paper
• Nanophytomedicine: Concept to Clinic

  2020cites this paper
• Revisiting Amantadine as A Treatment for Drug-Induced Movement Disorders

  2020cites this paper
• Lauric acid: Its role in behavioral modulation, neuro-inflammatory and oxidative stress markers in haloperidol induced Parkinson's disease.

  2020cites this paper
• Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

  2019cites this paper
• Pharmacokinetics and Pharmacodynamics of Antiviral Drugs in Special Population

  2019cites this paper
• Synthesis and evaluation of nitrocatechol derivatives of chalcone as inhibitors of monoamine oxidase and catechol-O-methyltransferase

  2019cites this paper
• Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies

  2019cites this paper
• Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets

  2019cites this paper
• C n and C n‐1 B Fullerenes as Potential Nanovehicles for Piribedil Neuroprotective Drug (n=20, 36 and 60)

  2019cites this paper
• Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies.

  2019cites this paper
• Scientific Reports of Medicinal Plants Used for the Prevention and Treatment of Neurodegenerative diseases

  2019cites this paper
• Influence of hemodialysis on pramipexole pharmacokinetics: Lessons from two cases and literature review

  2019cites this paper
• Unique hydrolysis of an ester-type prodrug of levodopa in human plasma-Relay-type role sharing between alpha-1 acid glycoprotein and human serum albumin.

  2019cites this paper
• Predicting the dopamine D2 receptor occupancy of ropinirole in rats using positron emission tomography and pharmacokinetic–pharmacodynamic modeling

  2019cites this paper
• Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies

  2019cites this paper
• Advancing synthetic therapies for the treatment of restless legs syndrome

  2019cites this paper
• Parkinson Disease.

  2019cites this paper
• Treatment of Parkinson’s Disease: Early, Late, and Combined

  2019cites this paper